Centogene n.v. announces unaudited consolidated earnings results for the third quarter and nine months ended september 30, 2019; provides revenue guidance for the full year 2019

Centogene n.v. announced unaudited consolidated earnings results for the third quarter and nine months ended september 30, 2019. for the quarter, the company reported revenue of €11,638,000 against €13,380,000 a year ago. operating loss was €2,843,000 against €1,132,000 a year ago. loss for the period was €4,276,000 against €1,225,000 a year ago. basic and diluted loss per share was €13 against €4 a year ago. for the nine months, the company reported revenue of €33,559,000 against €30,392,000 a year ago. operating loss was €13,823,000 against €7,192,000 a year ago. loss for the period was €15,839,000 against €7,847,000 a year ago. basic and diluted loss per share was €49 against €29 a year ago.for full year 2019, the company anticipates to have received over 130,000 order requests, allowing data repository to grow to approximately 500,000 patients. the company anticipates the total number of pharmaceutical partners to be over 40 partners by the end of 2019, and anticipate that revenue growth for full year 2019 will be approximately 20% when compared to full year 2018.
CNTG Ratings Summary
CNTG Quant Ranking